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Short Communication
Immunocytochemical Evidence That the
(3-Protein Precursor Is an Integral Component of
Neurofibrillary Tangles of Alzheimer's Disease
George Perry,* Peggy L. Richey,*
Sandra L. Siedlak,* Mark A. Smith,*
Paul Mulvihill,* David A. DeWitt,*
Jody Barnett,* Barry D. Greenberg,t and
Rajesh N. Kalariat
Division of Neuropathology,* Institute ofPathology, and
Department ofNeurology,* Case Western Reserve University,
Cleveland, Ohio; and Cephalon, Inc.,t West
Chester, Pennsylvania
Amyloid f (Af3) immunoreactivity has been dem-
onstrated in aUl extracelular neurofibrillary
tangles (E-NFT) and most intraneuronal neurofi-
brillary tangles (I-NF. We undertook this immu-
nocytochemical study to understand the relation-
ship between A(3 immunoreactivity localized in
NFT and (3-protein precursor (I3PP). We found
epitopes of amino-, mid-, and carboxyl-terminal
domains of fJPP in I-NFT and the majority of E-
NFT. NFT retained (3PP after ionic detergent ex-
traction, demonstrating that (PP is an integral
component ofNFT. Finding 8PP in regions ofA l
immunoreactivity raises the possibility that f3PP
or itsfragments associate with amyloid, and that
the stability ofA(3 is responsiblefor its dominance
in amyloid deposits. (Am J Pathol 1993,
143:1586-1593)
Immunocytochemical studies demonstrate that the
primary component of senile plaques, amyloid f (AP3),
is also associated with neurofibrillary tangles
(NFT).1-8 A,3 was reported in only a low percentage
of NFT in formalin-fixed, formic acid-denatured
samples. However, in tissue not fixed by aldehyde
and treated with low concentrations of formic acid, all
extracellular NFT (E-NFT), and many intraneuronal
NFT (I-NFT) were A,B immunoreactive.e These previ-
ous studies were limited to antibodies to AP3 epitopes,
which cannot distinguish between AP3 or a (3-protein
precursor (O3PP) fragment containing AP. The asso-
ciation of 3PP fragments with NFT is supported by the
presence of fPP epitopes in NFT, which lie outside the
AP3 domain.911 Yet, IPP was only localized to the fila-
ments of l-NFT10 11 and not to E-NFT.11 The absence
of ,BPP from E-NFT11 would suggest that f3PP is re-
moved, along with the neuronal cytoplasm, after neu-
ronal death. This interpretation is consistent with the
generalized cytoplasmic localization of ,BPP immuno-
reactivity in neurons.9 The peripheral association of
I3PP with NFT is also consistent with ultrastructural
localization of A,B to the amorphous covering of E-NFT
filaments3 and a report that some O3PP epitopes can
be removed from NFT by detergent.11
The aim of this study was to determine quantita-
tively whether 3PP-epitopes (amino-, mid-, and
carboxyl-terminal domains) are integral or peripheral
elements of NFT. The goal was to determine whether
the failure to detect OPP epitopes in E-NFT and
detergent-extracted NFT was related to poor epitope
preservation or exposure. In contrast with previous
reports, we show that ,BPP is specifically associated
with the majority of NFT; I-NFT and E-NFT. Further-
more, ,BPP is, like , retained after ionic detergent ex-
traction. Therefore, we suggest that the OPP in NFT
may provide a source for the A,B deposition on NFT.
Further, this study suggests that the metabolism of
some OPP molecules may occur extracellularly in
amyloid deposits. 1213
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Figure 1. Immunostaining ofNFT with anti-3PP4_62 (A) anti-(PP553--570 (B), or anti-3PP6489 (C) shows that numerous NFT are recognized
by antibodies directed to amino-, mid-, and carbhxyl-terminal domains of f3PP, respectively. OPP antibodies recognized NfT(some indicated by
large arrowheads) and neuronalperikarya (some indicated by small arrowheads). Scale bar = 50 ym.
Materials and Methods
Tissue
The hippocampus and adjacent temporal cortex of
five cases of Alzheimer's disease were studied
(ages 71, 77, 85, 87, and 90 years). Clinical and
pathological diagnoses were based on established
criteria. Qualitatively identical results were obtained
from all cases. Tissue taken at autopsy was fixed in
methacarn (methanol-chloroform-acetic acid, 6:3:1)
for 16 hours before paraffin embedding. Six-micron
sections were cut.
Homogenates of hippocampal tissue were pre-
pared by gently disrupting subiculum/Somer's sec-
tor gray matter (1:10, tissue:buffer ratio) in 50
mmol/L Tris-HCI, pH 7.6, with a Dounce homog-
enizer (Kontes Glass, Vineland, NJ). Aliquots of the
homogenate (10 p1) were placed on slides, dried for
16 hours at 37 C, and treated with Tris buffer (50
mmol/L Tris-HCI, pH 7.6), Tris buffer-1% Triton
X-100, or Tris buffer-1% sodium dodecyl sulfate
(SDS) for 20 minutes at room temperature. The
samples were then immunostained.
Immunological and Biochemical Reagents
Rabbit antisera raised to synthetic peptides ho-
mologous to three domains of ,BPP were used at a
dilution of 1:100: 1) anti-f3PP45_62: amino-terminal,
sequences 45-62 of PP695; 2) anti-pPP553-570:
mid-region, sequences 553-570 of f3PP695; and 3)
anti-f3PP648_689: carboxyl-terminal, sequences 648-
689 of 1PP695. None of the IPP antibodies recog-
nized T or neurofilament heavy subunit on immuno-
blots when used at the same concentration used for
immunostaining but, as expected, recognized 3PP
on immunodots. In preliminary experiments, we
found that formaldehyde fixation modified JPP epi-
topes such that they were not immunostained, and
pretreatment with 50% formic acid for 5 minutes at
room temperature was optimal for exposing OPP
epitopes.
Immunoabsorption consisted of incubating the
antiserum with 1 mg/ml of the appropriate synthetic
peptide for PP553-570 and PP648689 at 4 C for 16
hours before immunostaining. Immunoabsorption of
anti-f3PP45_62 was performed by passage through a
column containing PP45_62.
Heparan sulfate treatment consisted of incubat-
ing the sections for 1 hour at 37 C with 1 mg/ml
heparan sulfate (molecular weight, approximately 8
kd; Sigma, St. Louis, MO) in 50 mmol/L Tris-HCI, pH
7.6. Heparan sulfate was eluted by treating with 2
mol/L NaCI for 16 hours at room temperature. Hepa-
rinase treatment involved incubating sections with
heparinase 1 or heparinase 3 (1 U/ml; Sigma) in 10
mmol/L Tris-HCI, pH 7.0, and 20 mmol/L CaCI2 for
16 hours at room temperature.
Standard markers to quantitatively assess NFT
staining were basic fibroblast growth factor (bFGF)
binding,14 a probe for a form of heparan sulfate pro-
teoglycans specific to E-NFT, and Alz-50, a mono-
clonal antibody that only recognizes l-NFT. 14
The peroxidase anti-peroxidase method using
3,3'-diaminobenzidine as chromogen was used to
visualize immunoreactivity. Endogenous peroxidase
I
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Figure 2. Specificity ofantibody binding was determined by absorption with the immunogen. Immunostaining ofhippocampus with anti-(PP4562
(A), anti-,BPP553570 (B), and anti-f3PP648.,9 (C) is reduced bypreincubation with the respective immunogenic peptide: f3PP4`62 (D), f3PP55-570
(E), and f3PP64S689 (F). A and D, B and E, and C and F are adjacent sections; a landmark is indicated (*) in each set. Scale bars = 50 pm.
activity was quenched by treatment with 3% H202
in methanol for 30 minutes.
Quantitation of Stained Structures
The number of E-NFT and I-NFT recognized by the
various probes in adjacent sections was deter-
mined by counting five fields, 0.2 mm2 each, of the
x20 planapochromat objective of an Axiophot mi-
croscope (Carl Zeiss, Inc., Thornwood, NY). Land-
marks such as blood vessels were used to locate
the same five fields of the subiculum within each
group of adjacent sections. The fields evaluated
were chosen in regions of maximum density for
NFT. Immunostained NFT were defined by the in-
tense staining of flame-shaped bundles of fila-
ments; structures not displaying a filamentous
structure were not counted as NFT. Congo red
failed to recognize NFT after formic acid and, there-
fore, could not be used to augment our criteria to
identify NFT. Differential interference contrast (No-
marski) was used to identify the cytoplasm and
nucleus surrounding filaments of l-NFT and dis-
persed filaments of E-NFT.
Results
The initial goal of our study was immunocytochemi-
cal identification of specific O3PP domains in NFT.
Antibodies to the amino-terminal fPP45-62 (anti-
13PP45-62), mid-region 3PP553-570 (anti-fPP553-570),
and carboxyl-terminal 13PP648-689 (anti-1PP648-689)
I'll, "' ...... - ---.
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Figure 3. NFT detected by antisera to three OPP domains compared to standards for E-NFT(bFGF binding) and I-NFT(Alz-50; see Figure 4). Ad-jacent serial sections are shown in order and defined by a senile plaque (*). A: Anti-,/PPP45_,2; D: anti-OPP553-570; G: anti-PP,4,,-68, B, E, H:
Alz-50; C, F, 1: bFGF binding. Although individual NFT cannot aluways befolloued in consecutive sections, the density and tVpe ofNFT recognized
by these markers can be directly compared. Arrowheads indicate those cases uhere NFT recognized by different nmarkers are seen ini adjacent sec-
tions. Scale bars = 50 jm.
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all recognized NFT (Figure 1). Further, it was readily
apparent that 3PP is specifically associated with the
filaments of NFT in addition to being diffusely dis-
tributed throughout neuronal cytoplasm (Figure 1)
as previously reported." The specificity of each an-
tibody to O3PP was verified by immunoabsorption,
which reduced immunoreactivity (Figure 2).
The numbers of NFT recognized by the three 3PP
antisera were compared to Alz-5014 (I-NFT) and
bFGF14 binding (E-NFT; Figure 3). A quantitative as-
sessment in Figure 4 shows that O3PP antibodies
recognizes a majority of E-NFT and many I-NFT.
c01)
C)0-
I-NFT E-NFT I-NFT E-NFT i-NFT E-NFT
anti-APP 45-62 anti-APP 533-570 anti-APP 648-689
Figure 4. ile perceutuge O/ All l)It01111,. f3P71(i)iXill (1 (111
Ji)e/mln El cl ij 1 .,q mi/n compt)ared 1/wit/i tlbe )11 /numbr 1
ustained bc ilX , )11(11/ig (A.i\Il )d Alz () I i\l11 im tle immiedi
alte/l' adjacent sectio) tde]iie)lC'C tlt'.blst'e landmalr/lks. I ares(e tdie
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In a recent study, we showed that the heparan-
binding protein cholinesterase, which is associated
with NFT and senile plaques, can be specifically
dissociated by competition with heparan sulfate.15
As OPP has a heparan-binding domain,16 17 we
speculated that similar treatment might release 3PP
or its fragments. Indeed, pretreatment with heparan
sulfate reduces immunoreactivity. However, we
found that heparan sulfate blocks, rather than re-
moves, ,BPP, as a high salt treatment after heparan
sulfate reexposes OPP epitopes (Figure 5).
The inability to elute ,BPP with heparan sulfate
suggests that O3PP has an integral association with
NFT. To demonstrate this aspect, we prepared ho-
mogenates in 50 mmol/L Tris-HCI from hippocampal
grey matter rich in NFT and placed aliquots on mi-
croscope slides. The spots were dried and subse-
quently treated with Tris buffer alone or containing
Triton X-100 or SDS. After detergent extraction,
which dissolved most of the tissue, the sections
were immunostained with the antisera to J3PP, a pre-
immune serum, or an antiserum to T.18
The three ,BPP domains were retained after non-
ionic (Triton X-100) or ionic (SDS) detergent extrac-
tion (Figure 6). Quantitative evaluations were made
by direct comparison with the number of NFT con-
taining T epitopes. Comparison with T immunostain-
ing is essential, because NFT can be removed from
the slide by extraction, and T is retained by NFT
after SDS extraction.19 All three domains of 3PP are
retained by NFT morphologically identifical to those
containing T after either Triton X-100 or SDS (Table
1), indicating that 3PP, like T, is an integral compo-
nent of NFT.19
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Figure 6. OPP epitopes defined by anti-fPP4562 (A), anti-(PP553-570 (B), and anti-3PP6498 (C) were maintained after treatment with Tris
buffer as well as after Tns buffer-1% SDS: anti-(PP4562 (D), anti-3PP553570 (E), and anti-pPP6.H9 (F). Scale bar = 50 4m.
Table 1. fPP Epitopes Are Retained by NFT after either Nonionic (Triton X-100) or Ionic (SDS) Detergent Extraction to
Approximately the Same Extent as T Epitopes
Anti-(3PP4562 Anti-(3PP553570 Anti-3PP648-689 Anti-T Preimmune(n =6) (n =2) (n = 2) (n =6) (n =2)
Tris 126.2 + 6.9 14.5 ± 2.1 27 49 ± 7.5 2 ± 1.4
Triton 152 + 13.6 34 + 24 22.5 ± 6.4 54.8 ± 13.7 2.5 + 0.7
SDS 46.8 7.9 7 8.5 30 ± 25.5 13.3 4.4 0
Although in some cases there is considerable variability, all data indicate that j3PP is retained by NFT. The lower number of NFT after SDS
reflects removal of NFT from the slide. Data are expressed as the number of NFT stained in 1O-pI aliquots of a homogenate (1:10, tissue:buffer
ratio). Values are the mean + SE.
Discussion
Our results demonstrate that three non-contiguous
fPP epitopes are found in the majority of NFT. We
also show that although heparan sulfate proteogly-
cans may be responsible for initial f3PP incorpora-
tion, 1617,20 it is unlikely that they play a significant
role in retaining O3PP in NFT, as O3PP was not eluted
by heparan sulfate. We speculate that once associ-
ated, 3PP is retained in NFT by other interactions,
such as those described between T and fPP.21.22
Our findings differ from those of Yamaguchi and
co-workers.11 We readily detect three distinct 3PP
domains associated with NFT filaments and show
3PP in E-NFT and retention of I3PP after ionic
1592 Perry et al
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detergent extraction. These distinctions are highly
significant, as the properties noted by Yamaguichi
et al.11 lead them to conclude f3PP is an insignifi-
cant component of NFT, an interpretation inconsis-
tent with the findings reported here.
A provocative aspect of this study is that ,BPP se-
quences flanking the AP3 domain are apparently in-
tegral components in the majority of E-NFT. This
study raises the possibility that ,3PP or its fragments
may directly associate with NFT in addition to amy-
loid filaments9'23 in the extracellular space. This is
consistent with the results of several immunocyto-
chemical studies that identified fPP epitopes in AP3
deposits9'23 and with a more recent study identify-
ing fPP epitopes within highly purified amyloid
plaque cores.24 The presence of A13 in both NFT as
well as senile plaques may be due to the relative
stability of AP compared to other f3PP sequences to
catabolic degradation, 12,13,25,26 rather than being
the result of specific proteolytic events.
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